Effect of statin prescription persistence on time to subsequent ASCVD events
| Rehospitalisation outcomes | All ASCVD | AMI | Ischaemic stroke | |||
| aHR* | (95% CI) | aHR* | (95% CI) | aHR* | (95% CI) | |
| Persistence | ||||||
| Constant use period | Ref | Ref | Ref | |||
| Recent stop period | 1.16 | (1.13 to 1.19)† | 1.51 | (1.42 to 1.62)† | 1.38 | (1.32 to 1.45)† |
| Non-persistence period | 1.13 | (1.10 to 1.16)† | 1.60 | (1.49 to 1.71)† | 1.47 | (1.40 to 1.54)† |
| Intermittent use period | 1.26 | (1.21 to 1.31)† | 1.21 | (1.09 to 1.35)† | 1.26 | (1.17 to 1.35)† |